Pear CEO Sees Fulfilment And Reimbursement Challenges Ahead
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
You may also be interested in...
A few weeks after announcing that it was exploring its "strategic options," Pear Therapeutics announced that it is filing for bankruptcy and is not filling new prescriptions for its digital therapeutics.
Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.
Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic
Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.